September 22, 2022 News by Marisa Wexler, MS GA Depot Reduces Relapse Rates in Phase 3 Clinical Trial Treatment with GA Depot, an experimental long-acting form of glatiramer acetate that requires less frequent dosing than approved formulations, significantly reduced relapse rates among people with relapsing forms of multiple sclerosis (MS), according to top-line results from a Phase 3 clinical trial. “We are pleased with the topline…
April 4, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: GA Depot, Blood-brain Barrier, Mindfulness Use of GA Depot in Treating Progressive MS Given US Patent In the area of MS treatments, one major need is for medications that treat more than just the relapsing form of our disease. GA Depot might help fill that void. The U.S. patent the medication received says it’s…
April 1, 2022 News by Lindsey Shapiro, PhD Use of GA Depot in Treating Progressive MS Given US Patent Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, ā…
April 13, 2021 News by Patricia Inacio, PhD Phase 3 Trial of GA Depot as Monthly Relapsing MS Therapy Enrolling in US, Europe A Phase 3 trial investigating GA Depot, a long-acting, once-a-month injectable formulation of glatiramer acetate, is seeking patients with relapsing forms of multiple sclerosis (MS). The global study (NCT04121221) aims to include 960 adults, ages 18 to 55, diagnosed withĀ clinically isolated syndromeĀ (CIS),Ā relapsing-remitting…
June 17, 2020 News by Joana Carvalho, PhD Phase 3 Trial of GA Depot for Relapsing MS Advances With $20M Support Mapi Pharma, supported by an additionalĀ $20 million investment from its partner Mylan, will continue a Phase 3 trial assessing the safety, tolerability, and efficacy of GA Depot, its long-acting, once-a-month injectable formulation of glatiramer acetate. The study (NCT04121221),Ā which opened in October 2019,…
October 30, 2019 News by Alice MelĆ£o, MSc First Relapsing MS Patient Enrolled in Phase 3 Trial of Mapi Pharmaās Once-monthly Glatiramer Formulation A new Phase 3 clinical trial to explore the safety and efficacy of Mapi Pharmaās once-a-month injectable formulation of glatiramer acetate ā named GA Depot ā has started enrolling patients with relapsing multiple sclerosis (MS). The trial (NCT04121221) is expected to enroll approximately 960 participants, 18 to 55…
September 9, 2019 News by Alice MelĆ£o, MSc #ECTRIMS2019 – Mapi Pharma to Detail Latest Trial Data on GA Depot in Treating RRMS and PPMS Mapi PharmaĀ will presentĀ recent advances in its potential multiple sclerosis (MS) therapies, including GA Depot, at the 35thĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) opening this week. ECTRIMS runs from Wednesday through Friday, Sept. 11ā13, in Stockholm. Among the work disclosed will be…
April 11, 2018 News by Alice MelĆ£o, MSc Mapi Pharma, Mylan Partner to Develop Once-monthly Glatiramer Formulation Mylan andĀ Mapi Pharma will jointly develop and commercialize Glatiramer Acetate (GA) Depot, an investigative, long-lasting formulation of the commonly used multiple sclerosis (MS) therapyĀ CopaxoneĀ (marketed by Teva Phatmaceutical). Under the terms of the partnership, Mylan will acquire global marketing rights for the therapy. The companies are in…
February 1, 2018 News by Jose Marques Lopes, PhD Mapi Pharma Doses First PPMS Patient in Phase 2 Trial Evaluating GA Depot The Phase 2a trial of GA Depot (glatiramer acetate) for the treatment of primary progressive multiple sclerosis (PPMS) has dosed the first patient,Ā Mapi PharmaĀ recently announced. In the U.S., Copaxone (glatiramer acetate injection, marketed by Teva Pharmaceutical) is the standard therapy for relapsing-remitting multiple sclerosis (RRMS), which is…